— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected.
— Revenue jumped threefold to $44.8 million, versus $29.3 million expected. The results were helped by higher license fees and lower operating expenses.
— For fiscal 2020, company expects revenues between $60 million and $65 million. Operating expenses are projected to be between $165 million and $170 million.
— IMGN shares shot up 5.4% immediately following the announcement.
Leading stock indices continued the recent rally this week, with S&P 500 and Dow Jones Industrial Average setting new records helped mainly by the tech sector. Also, the overall sentiment
The health insurance sector has been facing multiple challenges from the virus crisis, but market-leading healthcare firm UnitedHealth Group (NYSE: UNH) maintained stable financial performance as customers of its core
United Airlines Holdings Inc. (NYSE: UAL) had a tough time in 2020 and its CFO literally bid “good riddance” to the year on its quarterly conference call. The company reported